Literature DB >> 17218539

Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway.

Gunther Marsche1, Michaela Semlitsch, Astrid Hammer, Sasa Frank, Bernd Weigle, Nina Demling, Kurt Schmidt, Werner Windischhofer, Georg Waeg, Wolfgang Sattler, Ernst Malle.   

Abstract

Signal transduction via the endothelial receptor for advanced glycation end products (RAGE) plays a key role in vascular inflammation. Recent observations have shown that the myeloperoxidase-H2O2-chloride system of activated phagocytes is highly up-regulated under inflammatory conditions where hypochlorous acid (HOCl) is formed as the major oxidant. Albumin, an in vivo carrier for myeloperoxidase is highly vulnerable to oxidation and a major representative of circulating advanced oxidized proteins during inflammatory diseases. Immunohistochemical studies performed in the present study revealed marked colocalization of HOCl-modified epitopes with RAGE and albumin in sections of human atheroma, mainly at the endothelial lining. We show that albumin modified with physiologically relevant concentrations of HOCl, added as reagent or generated by the myeloperoxidase-H2O2-chloride system, is a high affinity ligand for RAGE. Albumin, modified by HOCl in the absence of free amino acids/carbohydrates/lipids to exclude formation of AGE-like structures, induced a rapid, RAGE-dependent activation of extracellular signal-regulated kinase 1/2 and up-regulation of the proinflammatory mediator monocyte chemoattractant protein-1. Cellular activation could be blocked either by a specific polyclonal anti-RAGE IgG and/or a specific mitogen-activated protein-kinase kinase inhibitor. The present study demonstrates that HOCl-modified albumin acts as a ligand for RAGE and promotes RAGE-mediated inflammatory complications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17218539      PMCID: PMC4864469          DOI: 10.1096/fj.06-7439com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  40 in total

1.  Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high density lipoprotein on human umbilical venous endothelial cells.

Authors:  G Marsche; S Levak-Frank; O Quehenberger; R Heller; W Sattler; E Malle
Journal:  FASEB J       Date:  2001-04       Impact factor: 5.191

Review 2.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses.

Authors:  A M Schmidt; S D Yan; S F Yan; D M Stern
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

3.  Chemokine production by rat alveolar macrophages is inhibited by taurine chloramine.

Authors:  Yong Liu; Michael R Quinn
Journal:  Immunol Lett       Date:  2002-01-01       Impact factor: 3.685

4.  The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation.

Authors:  M M Anderson; J R Requena; J R Crowley; S R Thorpe; J W Heinecke
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

5.  Monocyte chemotactic protein-1 gene and protein expression in atherogenesis of hypercholesterolemic rabbits.

Authors:  Y L Chen; Y J Chang; M J Jiang
Journal:  Atherosclerosis       Date:  1999-03       Impact factor: 5.162

6.  N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression.

Authors:  T Kislinger; C Fu; B Huber; W Qu; A Taguchi; S Du Yan; M Hofmann; S F Yan; M Pischetsrieder; D Stern; A M Schmidt
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

7.  Hypochlorite-modified (lipo)proteins are present in rabbit lesions in response to dietary cholesterol.

Authors:  E Malle; G Wäg; J Thiery; W Sattler; H J Gröne
Journal:  Biochem Biophys Res Commun       Date:  2001-12-14       Impact factor: 3.575

Review 8.  Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice.

Authors:  W Peters; I F Charo
Journal:  Curr Opin Lipidol       Date:  2001-04       Impact factor: 4.776

9.  Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins.

Authors:  E Malle; G Waeg; R Schreiber; E F Gröne; W Sattler; H J Gröne
Journal:  Eur J Biochem       Date:  2000-07

10.  MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B.

Authors:  J Gosling; S Slaymaker; L Gu; S Tseng; C H Zlot; S G Young; B J Rollins; I F Charo
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

View more
  25 in total

1.  Cyanate is a novel inducer of endothelial icam-1 expression.

Authors:  Dalia El-Gamal; Michael Holzer; Martin Gauster; Rudolf Schicho; Veronika Binder; Viktoria Konya; Christian Wadsack; Rufina Schuligoi; Akos Heinemann; Gunther Marsche
Journal:  Antioxid Redox Signal       Date:  2011-10-14       Impact factor: 8.401

2.  Targeting neutrophil: new approach against hypertensive cardiac remodeling?

Authors:  Takashi Obama; Rosario Scalia; Satoru Eguchi
Journal:  Hypertension       Date:  2014-04-07       Impact factor: 10.190

3.  Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo.

Authors:  Gunther Marsche; Sasa Frank; Andelko Hrzenjak; Michael Holzer; Sabine Dirnberger; Christian Wadsack; Hubert Scharnagl; Tatjana Stojakovic; Akos Heinemann; Karl Oettl
Journal:  Circ Res       Date:  2009-01-29       Impact factor: 17.367

4.  Neutralization of X4- and R5-tropic HIV-1 NL4-3 variants by HOCl-modified serum albumins.

Authors:  Svenja Polzer; Melanie van Yperen; Martin Kirst; Birco Schwalbe; Heiner Schaal; Michael Schreiber
Journal:  BMC Res Notes       Date:  2010-06-02

5.  Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro.

Authors:  Gunther Marsche; Paul G Furtmüller; Christian Obinger; Wolfgang Sattler; Ernst Malle
Journal:  Cardiovasc Res       Date:  2008-02-23       Impact factor: 10.787

Review 6.  The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Expert Rev Mol Med       Date:  2009-03-12       Impact factor: 5.600

Review 7.  Myeloperoxidase: a target for new drug development?

Authors:  E Malle; P G Furtmüller; W Sattler; C Obinger
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 8.  Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications.

Authors:  A Bierhaus; P P Nawroth
Journal:  Diabetologia       Date:  2009-07-28       Impact factor: 10.122

9.  Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis.

Authors:  Ravichandran Ramasamy; Shi Fang Yan; Kevan Herold; Raphael Clynes; Ann Marie Schmidt
Journal:  Ann N Y Acad Sci       Date:  2008-04       Impact factor: 5.691

10.  Endothelin (ET)-1 and ET-3 promote expression of c-fos and c-jun in human choriocarcinoma via ET(B) receptor-mediated G(i)- and G(q)-pathways and MAP kinase activation.

Authors:  A Rauh; W Windischhofer; A Kovacevic; T DeVaney; E Huber; M Semlitsch; H-J Leis; W Sattler; E Malle
Journal:  Br J Pharmacol       Date:  2008-03-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.